europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

DSM’s Patricia Malarkey appointed as new Chair of EuropaBio

23/06/2022
PRESS RELEASE
June 23, 2022, Brussels - Today, EuropaBio’s General Assembly confirmed the appointment of Patricia Malarkey as the new Chair of the association. Patricia Malarkey is the global Chief Science Officer at DSM.

Commenting on her appointment, Patricia Malarkey highlighted: ‘I am delighted to take on the role of Chair of the Board at EuropaBio at a time of global transformation where biotechnology plays a key role to achieve a more sustainable and healthier society. EuropaBio has the advantage of being able to look across biotechnology sectors and champion innovation. Its members encompass companies of all sizes plus the regional and national associations that create the fabric of Europe. Now, more than ever before, these voices need to join together to help Europe build the innovation framework for the benefit of all and to support the EU to deliver on its Green Deal ambitions. I would like to thank Andrew Topen for his leadership of EuropaBio over the last two years especially in building a solid advocacy and visibility of the organisation.’

Dr Claire Skentelbery, Director General of EuropaBio added ‘Biotechnology is accelerating its impact across sectors, especially in the transition onto a post-fossil fuel world for manufacture and sustainable agriculture. DSM represents the significant focus that multi-national companies now have for biotechnology and its own transformation reflects the fast growing investment and race for global competitiveness. We are delighted that DSM will lead EuropaBio into a new era for economic growth from biotech.’

Mrs Malarkey will take on the new role with immediate effect for a two year mandate.

DSM’s Patricia Malarkey appointed as new Chair of EuropaBio


Download

Share
Alexandra Simionca
Alexandra Simionca

Related posts

23/03/2023

Unlocking the Potential of Biotechnology Innovation for Patients


Read more
16/03/2023

Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future


Read more
07/03/2023

Disc Medicine joins EuropaBio: life-changing medicines for patients with hematologic disorders


Read more
06/03/2023

Can the Pharmaceutical Strategy Deliver for Europe?


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member